{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:25:31Z","timestamp":1791685531606,"version":"4.3.4"},"reference-count":337,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2632025ZD10"],"award-info":[{"award-number":["2632025ZD10"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005145","name":"Basic Research Program of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20243061"],"award-info":[{"award-number":["BK20243061"]}],"id":[{"id":"10.13039\/501100005145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010097","name":"China Association for Science and Technology","doi-asserted-by":"publisher","award":["2024-2026QNRC001"],"award-info":[{"award-number":["2024-2026QNRC001"]}],"id":[{"id":"10.13039\/100010097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024 T171037"],"award-info":[{"award-number":["2024 T171037"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZSM202301035"],"award-info":[{"award-number":["SZSM202301035"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.addr.2026.115876","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:24:22Z","timestamp":1776871462000},"page":"115876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Engineering brain-penetrant PROTACs: Bridging molecular design and CNS delivery"],"prefix":"10.1016","volume":"234","author":[{"given":"Xinuo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanyou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiulun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115876_bb0005","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115876_bb0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41573-023-00823-1","article-title":"Targeting synapse function and loss for treatment of neurodegenerative diseases","volume":"23","author":"Dejanovic","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115876_bb0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tcb.2020.01.008","article-title":"Mechanisms linking mitochondrial dysfunction and proteostasis failure","volume":"30","author":"Lu","year":"2020","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.addr.2026.115876_bb0020","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/nn.2433","article-title":"Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses","volume":"12","author":"Abramov","year":"2009","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.addr.2026.115876_bb0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115876_bb0030","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104376","article-title":"PROTAC 2.0: expanding the frontiers of targeted protein degradation","volume":"30","author":"Cornu","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2026.115876_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2014.117","article-title":"Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies","volume":"47","author":"Ciechanover","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.addr.2026.115876_bb0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2004.06.002","article-title":"Importance of p-glycoprotein at blood-tissue barriers","volume":"25","author":"Fromm","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2026.115876_bb0050","article-title":"Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles","volume":"16","author":"He","year":"2022","journal-title":"Mater. Today, Bio"},{"key":"10.1016\/j.addr.2026.115876_bb0055","article-title":"Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy","volume":"9","author":"Zhang","year":"2022","journal-title":"Adv. Sci. Weinh. Baden-Wurtt. Ger."},{"key":"10.1016\/j.addr.2026.115876_bb0060","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/pharmaceutics12100986","article-title":"Controlled delivery of BET-PROTACs: in vitro evaluation of MZ1-loaded polymeric antibody conjugated nanoparticles in breast cancer","volume":"12","author":"Cimas","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115876_bb0065","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1039\/C6CS00076B","article-title":"Blood-brain barrier shuttle peptides: An emerging paradigm for brain delivery","volume":"45","author":"Oller-Salvia","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0070","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1016\/j.apsb.2022.02.009","article-title":"A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and m2 macrophages polarization","volume":"B 12","author":"Yang","year":"2022","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.addr.2026.115876_bb0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-025-00481-w","article-title":"Nose-to-brain drug delivery: from bench to bedside","volume":"14","author":"Drath","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.addr.2026.115876_bb0080","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0085","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/pharmaceutics16020226","article-title":"Interspecies brain PBPK modeling platform to predict passive transport through the blood-brain barrier and assess target site disposition","volume":"16","author":"Mehta","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115876_bb0090","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1038\/s41467-022-34807-3","article-title":"DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115876_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.celbio.2025.100130","article-title":"Lab-in-the-loop machine learning for brain-targeting delivery system design","volume":"1","author":"Qiu","year":"2025","journal-title":"Cell Biomater."},{"key":"10.1016\/j.addr.2026.115876_bb0100","first-page":"453","article-title":"Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation, cell","volume":"23","author":"Chu","year":"2016","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb0105","doi-asserted-by":"crossref","first-page":"11530","DOI":"10.1002\/anie.201706529","article-title":"Discovery of small molecules that induce the degradation of huntingtin","volume":"56","author":"Tomoshige","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.addr.2026.115876_bb0110","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bmcl.2018.01.012","article-title":"Degradation of huntingtin mediated by a hybrid molecule composed of IAP antagonist linked to phenyldiazenyl benzothiazole derivative","volume":"28","author":"Tomoshige","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2026.115876_bb0115","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.45457","article-title":"Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models","volume":"8","author":"Silva","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.addr.2026.115876_bb0120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2018.01.063","article-title":"Discovery of a keap1-dependent peptide PROTAC to knockdown tau by ubiquitination-proteasome degradation pathway","volume":"146","author":"Lu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.133680","article-title":"Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment","volume":"275","author":"Fan","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2026.115876_bb0130","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41573-023-00652-2","article-title":"Delivering on the promise of protein degraders","volume":"22","author":"O'Brien Laramy","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115876_bb0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","article-title":"Blood-brain barrier delivery","volume":"12","author":"Pardridge","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2026.115876_bb0140","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nm.3407","article-title":"Development, maintenance and disruption of the blood-brain barrier","volume":"19","author":"Obermeier","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115876_bb0145","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow Metab.: Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.addr.2026.115876_bb0150","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by PROTACs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.addr.2026.115876_bb0155","doi-asserted-by":"crossref","first-page":"E7285","DOI":"10.1073\/pnas.1803662115","article-title":"Delineating the role of cooperativity in the design of potent PROTACs for BTK","volume":"115","author":"Zorba","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2026.115876_bb0160","doi-asserted-by":"crossref","first-page":"16930","DOI":"10.1021\/jacs.2c05499","article-title":"Discovery of XL01126: a potent, fast, cooperative, selective, orally bioavailable, and blood-brain barrier penetrant PROTAC degrader of leucine-rich repeat kinase 2","volume":"144","author":"Liu","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115876_bb0165","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb0170","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/med.2610020404","article-title":"Molecular conformation and biological activity of central nervous system active drugs","volume":"2","author":"Andrews","year":"1982","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0175","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1161\/STROKEAHA.123.043764","article-title":"CNS drug delivery in stroke: improving therapeutic translation from the bench to the bedside","volume":"55","author":"Ronaldson","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.addr.2026.115876_bb0180","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0185","first-page":"952","article-title":"The role of reversible and irreversible covalent chemistry in targeted protein degradation, cell","volume":"28","author":"Kiely-Collins","year":"2021","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0195","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cbpa.2006.06.014","article-title":"A practical view of \u201cdruggability\u201d","volume":"10","author":"Keller","year":"2006","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.934337","article-title":"Key considerations in targeted protein degradation drug discovery and development","volume":"10","author":"Qin","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0205","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1208\/s12248-019-0402-2","article-title":"The evolving druggability and developability space: chemically modified new modalities and emerging small molecules","volume":"22","author":"Yang","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115876_bb0210","doi-asserted-by":"crossref","first-page":"13029","DOI":"10.1021\/acs.jmedchem.2c00877","article-title":"Linker-dependent folding rationalizes PROTAC cell permeability","volume":"65","author":"Poongavanam","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0215","doi-asserted-by":"crossref","first-page":"15711","DOI":"10.1021\/acs.jmedchem.5c00718","article-title":"Enhancing solubility in VHL-based PROTACs: optimized USP7 degraders for improved developability","volume":"68","author":"Wittenburg","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0220","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.phrs.2014.06.004","article-title":"Structural determinants of peripheral o-arylcarbamate FAAH inhibitors render them dual substrates for abcb1 and abcg2 and restrict their access to the brain","volume":"87","author":"Moreno-Sanz","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.addr.2026.115876_bb0225","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1021\/acs.jmedchem.9b01220","article-title":"The blood-brain barrier (BBB) score","volume":"62","author":"Gupta","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0230","doi-asserted-by":"crossref","first-page":"9299","DOI":"10.1021\/jacs.8b05807","article-title":"3-fluoro-4-hydroxyprolines: synthesis, conformational analysis, and stereoselective recognition by the VHL e3 ubiquitin ligase for targeted protein degradation","volume":"140","author":"Testa","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115876_bb0235","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","article-title":"Structural and physicochemical features of oral PROTACs","volume":"67","author":"Schade","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0240","doi-asserted-by":"crossref","first-page":"9584","DOI":"10.1021\/acs.jmedchem.5c00358","article-title":"In vitro ADME profiling of PROTACs: successes, challenges, and lessons learned from analysis of clinical PROTACs from a diverse physicochemical space","volume":"68","author":"Srivastava","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100066","article-title":"Applications of contemporary tools to measure plasma protein binding of targeted protein degraders, drug metab","volume":"53","author":"Niosi","year":"2025","journal-title":"Dispos.: Biol. Fate Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.101175","article-title":"Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling","volume":"15","author":"He","year":"2025","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.addr.2026.115876_bb0255","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.cell.2025.03.036","article-title":"CD36-mediated endocytosis of proteolysis-targeting chimeras","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115876_bb0260","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1535-7163.MCT-23-0747","article-title":"PROTACs: current and future potential as a precision medicine strategy to combat cancer","volume":"23","author":"Rutherford","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2026.115876_bb0265","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202520235","article-title":"Ionizable nano-PROTAC overcomes endosomal entrapment for enhanced LRG1 degradation and tumor suppression","volume":"65","author":"Min","year":"2026","journal-title":"Angew. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2023.108103","article-title":"Endosomal escape for cell-targeted proteins. Going out after going in","volume":"63","author":"Volta-Duran","year":"2023","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.addr.2026.115876_bb0275","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood-brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0280","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2006.10.0677","article-title":"Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm","volume":"25","author":"Gerstner","year":"2007","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115876_bb0285","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11030-014-9562-2","article-title":"Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability","volume":"19","author":"Garg","year":"2015","journal-title":"Mol. Divers."},{"key":"10.1016\/j.addr.2026.115876_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107554","article-title":"Dysfunction of ABC transporters at the blood-brain barrier: role in neurological disorders","volume":"213","author":"Gil-Martins","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.addr.2026.115876_bb0295","doi-asserted-by":"crossref","first-page":"eabn2707","DOI":"10.1126\/scisignal.abn2707","article-title":"The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells","volume":"15","author":"Kurimchak","year":"2022","journal-title":"Sci. Signal."},{"key":"10.1016\/j.addr.2026.115876_bb0300","first-page":"291","article-title":"The efflux pump ABCC1\/MRP1 constitutively restricts PROTAC sensitivity in cancer cells, cell","volume":"32","author":"Wolf","year":"2025","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb0305","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2023.04.020","article-title":"A review on in vitro model of the blood-brain barrier (BBB) based on hCMEC\/D3 cells","volume":"358","author":"Qi","year":"2023","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.addr.2026.115876_bb0310","doi-asserted-by":"crossref","first-page":"11615","DOI":"10.1021\/acs.jmedchem.0c00793","article-title":"Understanding the metabolism of proteolysis targeting chimeras (PROTACs): the next step toward pharmaceutical applications","volume":"63","author":"Goracci","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0315","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1021\/acs.jmedchem.2c02076","article-title":"Mathematical model for covalent proteolysis targeting chimeras: thermodynamics and kinetics underlying catalytic efficiency","volume":"66","author":"Chaudhry","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0320","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1021\/acs.jcim.4c01227","article-title":"Characterizing the cooperative effect of PROTAC systems with end-point binding free energy calculation","volume":"64","author":"Xu","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.addr.2026.115876_bb0325","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the role of linker design in proteolysis targeting chimeras","volume":"64","author":"Bemis","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0330","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41420-025-02392-1","article-title":"MAGL targeted PROTAC degrader simultaneously enhances p53 for synergistic treatment of glioblastoma stem cell","volume":"11","author":"Yuan","year":"2025","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.addr.2026.115876_bb0335","doi-asserted-by":"crossref","first-page":"8857","DOI":"10.1038\/s41467-025-63928-8","article-title":"Discovery of a CNS active GSK3 degrader using orthogonally reactive linker screening","volume":"16","author":"Holmqvist","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115876_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2024.1370509","article-title":"Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?","volume":"17","author":"Kuemper","year":"2024","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.addr.2026.115876_bb0345","article-title":"In vivo self-assembly of PROTACs by bioorthogonal chemistry for precision cancer therapy","volume":"64","author":"Xie","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.addr.2026.115876_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102279","article-title":"Ubiquitin e3 ligases assisted technologies in protein degradation: sharing pathways in neurodegenerative disorders and cancer","volume":"96","author":"Kaushik","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0355","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113749","article-title":"Developments of CRBN-based PROTACs as potential therapeutic agents","volume":"225","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0365","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in alzheimer-like models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2026.115876_bb0370","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/cdd.2011.94","article-title":"Glycogen synthase kinase 3\u03b2 inhibitors protect hippocampal neurons from radiation-induced apoptosis by regulating MDM2-p53 pathway","volume":"19","author":"Thotala","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.addr.2026.115876_bb0375","doi-asserted-by":"crossref","first-page":"8701","DOI":"10.1523\/JNEUROSCI.2133-14.2015","article-title":"Loss of the neuron-specific f-box protein FBXO41 models an ataxia-like phenotype in mice with neuronal migration defects and degeneration in the cerebellum, j. neurosci.: off","volume":"35","author":"Mukherjee","year":"2015","journal-title":"J. Soc. Neurosci."},{"key":"10.1016\/j.addr.2026.115876_bb0380","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1038\/s41598-019-44589-2","article-title":"Fbxo41 promotes disassembly of neuronal primary cilia","volume":"9","author":"King","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2026.115876_bb0385","doi-asserted-by":"crossref","first-page":"12016","DOI":"10.1073\/pnas.0802261105","article-title":"Deficiency in ubiquitin ligase TRIM2 causes accumulation of neurofilament light chain and neurodegeneration","volume":"105","author":"Balastik","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2026.115876_bb0390","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1471-4159.2010.06971.x","article-title":"The e3-ubiquitin ligase TRIM2 regulates neuronal polarization","volume":"117","author":"Khazaei","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.addr.2026.115876_bb0395","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s40364-024-00691-w","article-title":"FBXL16: a new regulator of neuroinflammation and cognition in alzheimers disease through the ubiquitination-dependent degradation of amyloid precursor protein","volume":"12","author":"Qu","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.addr.2026.115876_bb0400","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41419-020-03278-z","article-title":"TRAF3 mediates neuronal apoptosis in early brain injury following subarachnoid hemorrhage via targeting TAK1-dependent MAPKs and NF-\u03baB pathways","volume":"12","author":"Zhou","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2026.115876_bb0405","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1021\/acsomega.2c07904","article-title":"Decoding the role of MDM2 as a potential ubiquitin e3 ligase and identifying the therapeutic efficiency of alkaloids against MDM2 in combating glioblastoma","volume":"8","author":"Sharma","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.addr.2026.115876_bb0410","first-page":"47","article-title":"RING-type e3 ligases: master manipulators of e2 ubiquitin-conjugating enzymes and ubiquitination","volume":"2014","author":"Metzger","year":"1843","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2026.115876_bb0415","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08533-3","article-title":"Converging mechanism of UM171 and KBTBD4 neomorphic cancer mutations","volume":"639","author":"Xie","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115876_bb0420","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.3390\/ijms26052304","article-title":"Unraveling the roles of UBE3A in neurodevelopment and neurodegeneration","volume":"26","author":"Yang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115876_bb0425","article-title":"The e3 ubiquitin ligase RNF216 contains a linear ubiquitin chain-determining-like domain that functions to regulate dendritic arborization and dendritic spine type in hippocampal neurons, bioRxiv: Prepr","author":"Kadirvelu","year":"2023","journal-title":"Serv. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb0430","doi-asserted-by":"crossref","first-page":"29106","DOI":"10.1074\/jbc.M302763200","article-title":"Dorfin localizes to lewy bodies and ubiquitylates synphilin-1","volume":"278","author":"Ito","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0435","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neuroscience.2023.08.036","article-title":"NEDD4 like e3 ubiquitin protein ligase represses astrocyte activation and aggravates neuroinflammation in mice with depression via paired box 6 ubiquitination","volume":"530","author":"Wang","year":"2023","journal-title":"Neuroscience"},{"key":"10.1016\/j.addr.2026.115876_bb0440","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.98181.3","article-title":"Upregulated expression of ubiquitin ligase TRIM21 promotes PKM2 nuclear translocation and astrocyte activation in experimental autoimmune encephalomyelitis","volume":"13","author":"Yang","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.addr.2026.115876_bb0445","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/cns.12557","article-title":"The e3 ubiquitin ligase c-cbl inhibits microglia-mediated CNS inflammation by regulating PI3K\/akt\/NF-\u03baB pathway","volume":"22","author":"Dong","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.addr.2026.115876_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1292022","article-title":"Biology of pellino1: a potential therapeutic target for inflammation in diseases and cancers","volume":"14","author":"Yan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115876_bb0455","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s10571-023-01337-5","article-title":"Tripartite motif protein family in central nervous system diseases","volume":"43","author":"Pan","year":"2023","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.addr.2026.115876_bb0460","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3390\/biomedicines13040810","article-title":"Cullin-RING ubiquitin ligases in neurodevelopment and neurodevelopmental disorders","volume":"13","author":"Ashitomi","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2026.115876_bb0465","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","article-title":"Drug delivery to the central nervous system","volume":"7","author":"Nance","year":"2022","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.addr.2026.115876_bb0470","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jconrel.2023.08.060","article-title":"Influence of focused ultrasound on locoregional drug delivery to the brain: potential implications for brain tumor therapy","volume":"362","author":"Uribe Cardenas","year":"2023","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.addr.2026.115876_bb0475","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0002-9440(10)65722-7","article-title":"Lewy bodies contain altered alpha-synuclein in brains of many familial alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes","volume":"153","author":"Lippa","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.addr.2026.115876_bb0480","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115876_bb0485","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/ana.410440324","article-title":"Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein","volume":"44","author":"Tu","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.addr.2026.115876_bb0490","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological \u03b1-synuclein transmission initiates parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115876_bb0495","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in parkinson's disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115876_bb0500","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with parkinson's disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115876_bb0505","first-page":"1","article-title":"Neuroanatomy and pathology of sporadic parkinson's disease","volume":"201","author":"Braak","year":"2009","journal-title":"Adv. Anat. Embryol. Cell Biol."},{"key":"10.1016\/j.addr.2026.115876_bb0510","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","article-title":"Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases","volume":"21","author":"Jucker","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.addr.2026.115876_bb0515","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.3457","article-title":"Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases","volume":"20","author":"Guo","year":"2014","journal-title":"Nat. Med."},{"issue":"Suppl","key":"10.1016\/j.addr.2026.115876_bb0520","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/nm1066","article-title":"Protein aggregation and neurodegenerative disease","volume":"10","author":"Ross","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115876_bb0525","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/ijms20030719","article-title":"Novel approaches for the treatment of alzheimer's and parkinson's disease","volume":"20","author":"Van Bulck","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115876_bb0530","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/anie.202004746","article-title":"PROTACs and other chemical protein degradation technologies for the treatment of neurodegenerative disorders","volume":"60","author":"Tomoshige","year":"2021","journal-title":"Angew. Chem. (Int. Ed, Engl.)"},{"key":"10.1016\/j.addr.2026.115876_bb0535","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-020-00924-z","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2026.115876_bb0540","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1347987","article-title":"The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets","volume":"16","author":"Adamu","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.addr.2026.115876_bb0545","doi-asserted-by":"crossref","DOI":"10.1126\/science.adx0043","article-title":"Neuroinflammation across neurological diseases","volume":"388","author":"Shi","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115876_bb0550","doi-asserted-by":"crossref","DOI":"10.1038\/s41583-025-00976-5","article-title":"Dynamic modulation of the blood-brain barrier in the healthy brain","author":"Friedman","year":"2025","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.addr.2026.115876_bb0555","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115876_bb0560","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400008","article-title":"Inducing targeted protein degradation: from chemical biology to drug discovery and clinical applications. Edited by philipp cromm","volume":"19","author":"McAulay","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.addr.2026.115876_bb0565","doi-asserted-by":"crossref","first-page":"eado6492","DOI":"10.1126\/sciadv.ado6492","article-title":"Mechanism of degrader-targeted protein ubiquitinability","volume":"10","author":"Crowe","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2026.115876_bb0570","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41589-019-0411-6","article-title":"Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 e3 ligase complex","volume":"16","author":"Bussiere","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb0575","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1038\/s41467-025-62099-w","article-title":"Unveiling the hidden interactome of CRBN molecular glues","volume":"16","author":"Baek","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115876_bb0580","doi-asserted-by":"crossref","first-page":"34672","DOI":"10.1021\/jacs.5c09843","article-title":"Enzyme-activated sugar-coated bifunctional degraders","volume":"147","author":"Zhu","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115876_bb0585","article-title":"Challenges in predicting PROTAC-mediated protein-protein interfaces with AlphaFold reveal a general limitation on small interfaces","volume":"5","author":"Pereira","year":"2025","journal-title":"Bioinf. Adv"},{"key":"10.1016\/j.addr.2026.115876_bb0590","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1038\/s41467-025-57823-5","article-title":"Identification of a non-inhibitory aptameric ligand to CRL2ZYG11B e3 ligase for targeted protein degradation","volume":"16","author":"Yang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115876_bb0595","first-page":"3549","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models, clin. cancer res.: off. j. Am. Assoc","volume":"30","author":"Gough","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2026.115876_bb0600","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood-brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb0605","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.7150\/thno.21254","article-title":"Current strategies for brain drug delivery","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2026.115876_bb0610","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2016.10.022","article-title":"Intracerebroventricular delivery as a safe, long-term route of drug administration","volume":"67","author":"Cohen-Pfeffer","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.addr.2026.115876_bb0615","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","article-title":"Evolving drug delivery strategies to overcome the blood brain barrier","volume":"22","author":"Hersh","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2026.115876_bb0620","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1586\/14737140.7.12s.S79","article-title":"Convection-enhanced delivery for treatment of brain tumors","volume":"7","author":"Ferguson","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.addr.2026.115876_bb0625","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/IJN.S61288","article-title":"Current approaches to enhance CNS delivery of drugs across the brain barriers","volume":"9","author":"Lu","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2026.115876_bb0630","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000338222","article-title":"Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations","volume":"90","author":"Baizabal Carvallo","year":"2012","journal-title":"Stereotact. Funct. Neurosurg."},{"key":"10.1016\/j.addr.2026.115876_bb0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2019.11.009","article-title":"The blood-brain barrier: physiology and strategies for drug delivery","volume":"165\u2013166","author":"Pandit","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0640","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1039\/C8CS00805A","article-title":"Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics","volume":"48","author":"Tang","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0645","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4155\/tde.10.50","article-title":"Viral vectors and delivery strategies for CNS gene therapy","volume":"1","author":"Gray","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2026.115876_bb0650","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coviro.2016.08.006","article-title":"Crossing the blood-brain-barrier with viral vectors","volume":"21","author":"Fu","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.addr.2026.115876_bb0655","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.addr.2026.115876_bb0660","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115876_bb0665","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2011.98","article-title":"Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.addr.2026.115876_bb0670","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.addr.2026.115876_bb0675","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.adm8386","article-title":"An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery","volume":"384","author":"Huang","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115876_bb0680","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40824-023-00385-8","article-title":"Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)","volume":"27","author":"Wang","year":"2023","journal-title":"Biomater. Res."},{"key":"10.1016\/j.addr.2026.115876_bb0685","article-title":"Genetically-encoded degraders as versatile modulators of intracellular therapeutic targets","volume":"27","author":"Dai","year":"2023","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"10.1016\/j.addr.2026.115876_bb0690","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Ling","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115876_bb0695","first-page":"763","article-title":"Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice, Mol. Ther.: J. Am. Soc","volume":"12","author":"Themis","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2026.115876_bb0700","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/71545","article-title":"Researchers and regulators reflect on first gene therapy death","volume":"6","author":"Hollon","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115876_bb0705","first-page":"561","article-title":"Gene therapy put on hold as third child develops cancer","volume":"433","author":"Check","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115876_bb0710","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fnins.2017.00082","article-title":"Exosomes: origins and therapeutic potential for neurodegenerative disease","volume":"11","author":"Sarko","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.addr.2026.115876_bb0715","first-page":"547","article-title":"Emerging technologies for delivery of biotherapeutics and gene therapy across the blood-brain barrier, biodrugs: Clin","volume":"32","author":"Stanimirovic","year":"2018","journal-title":"Immunother. Biopharm. Gene Ther."},{"key":"10.1016\/j.addr.2026.115876_bb0720","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","article-title":"Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges","volume":"B 6","author":"Ha","year":"2016","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.addr.2026.115876_bb0725","doi-asserted-by":"crossref","DOI":"10.1186\/2045-8118-10-4","article-title":"Method for isolation and molecular characterization of extracellular microvesicles released from brain endothelial cells","volume":"10","author":"Haqqani","year":"2013","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.addr.2026.115876_bb0730","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115876_bb0735","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/mds.25978","article-title":"Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice","volume":"29","author":"Cooper","year":"2014","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.addr.2026.115876_bb0740","article-title":"Exosomes as natures nano carriers: promising drug delivery tools and targeted therapy for glioma","volume":"182","author":"Rana","year":"2025","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2026.115876_bb0745","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1161\/01.CIR.0000012747.53592.6A","article-title":"Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the multicenter rt-PA stroke survey","volume":"105","author":"Tanne","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2026.115876_bb0750","first-page":"177","article-title":"Exosome-coated tPA\/catalase nanoformulation for thrombolytic therapy","volume":"10","author":"Khalil","year":"2023","journal-title":"Bioeng. (Basel Switz.)"},{"key":"10.1016\/j.addr.2026.115876_bb0755","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/STROKEAHA.118.023815","article-title":"Clinical effects of early edaravone use in acute ischemic stroke patients treated by endovascular reperfusion therapy","volume":"50","author":"Enomoto","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.addr.2026.115876_bb0760","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1021\/acs.molpharmaceut.0c00245","article-title":"Edaravone-loaded macrophage-derived exosomes enhance neuroprotection in the rat permanent middle cerebral artery occlusion model of stroke","volume":"17","author":"Li","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115876_bb0765","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1049\/nbt2.12003","article-title":"A novel brain targeted plasma exosomes enhance the neuroprotective efficacy of edaravone in ischemic stroke","volume":"15","author":"Guo","year":"2021","journal-title":"IET Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115876_bb0770","article-title":"Engineered exosomes as precision tools for brain-targeted drug delivery and treatment of central nervous system diseases","volume":"0","author":"Jin","year":"2026","journal-title":"Cell Biomater."},{"key":"10.1016\/j.addr.2026.115876_bb0775","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12951-025-03352-8","article-title":"Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies","volume":"23","author":"Mehdizadeh","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115876_bb0780","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","article-title":"Transport of drugs across the blood-brain barrier by nanoparticles","volume":"161","author":"Wohlfart","year":"2012","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.addr.2026.115876_bb0785","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/238428","article-title":"Nanoparticles for brain drug delivery","volume":"2013","author":"Masserini","year":"2013","journal-title":"ISRN Biochem."},{"key":"10.1016\/j.addr.2026.115876_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111389","article-title":"Phytochemical delivery through nanocarriers: a review","volume":"197","author":"Ahmad","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.addr.2026.115876_bb0795","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jconrel.2019.10.034","article-title":"Nanoparticle-mediated approaches for alzheimer's disease pathogenesis, diagnosis, and therapeutics","volume":"314","author":"Hettiarachchi","year":"2019","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.addr.2026.115876_bb0800","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40580-018-0168-8","article-title":"Therapeutic nanoplatforms and delivery strategies for neurological disorders","volume":"5","author":"Kang","year":"2018","journal-title":"Nano Convergence"},{"key":"10.1016\/j.addr.2026.115876_bb0805","doi-asserted-by":"crossref","first-page":"11357","DOI":"10.2147\/IJN.S484838","article-title":"Nanoparticle-based drug delivery systems enhance treatment of cognitive defects","volume":"19","author":"Wilar","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2026.115876_bb0810","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3109\/03639045.2014.991400","article-title":"Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting","volume":"41","author":"Jafarieh","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2026.115876_bb0815","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1021\/acsnano.6b04268","article-title":"Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy","volume":"10","author":"Lin","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115876_bb0820","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0006-8993(95)00023-J","article-title":"Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)","volume":"674","author":"Kreuter","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.addr.2026.115876_bb0825","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/mp900306x","article-title":"ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model","volume":"7","author":"Mulik","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115876_bb0830","first-page":"35","article-title":"Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of alzheimers disease, Wiley interdiscip. Rev., nanomed","volume":"2","author":"Kulkarni","year":"2010","journal-title":"Nanobiotechnology"},{"key":"10.1016\/j.addr.2026.115876_bb0835","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1016\/j.biomaterials.2011.07.004","article-title":"Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery","volume":"32","author":"Guo","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115876_bb0840","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5607\/en.2014.23.3.246","article-title":"Increasing the efficiency of parkinson's disease treatment using a poly(lactic-co-glycolic acid) (PLGA) based L-DOPA delivery system","volume":"23","author":"Gambaryan","year":"2014","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.addr.2026.115876_bb0845","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.freeradbiomed.2013.07.042","article-title":"Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism","volume":"65","author":"Tiwari","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.addr.2026.115876_bb0850","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijpharm.2005.01.043","article-title":"Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier","volume":"295","author":"Lu","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115876_bb0855","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1016\/j.biomaterials.2011.02.044","article-title":"Angiopep-conjugated poly(ethylene glycol)-co-poly(\u03b5-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma","volume":"32","author":"Xin","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115876_bb0860","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/biomedicines8010013","article-title":"Multifunctional polymeric nanoplatforms for brain diseases diagnosis, therapy and theranostics","volume":"8","author":"Shakeri","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2026.115876_bb0865","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1166\/jnn.2003.077","article-title":"Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain","volume":"4","author":"Kreuter","year":"2004","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115876_bb0870","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0024-3205(99)00619-0","article-title":"Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice","volume":"66","author":"Schroeder","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2026.115876_bb0875","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nmat2444","article-title":"Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA","volume":"8","author":"Woodrow","year":"2009","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2026.115876_bb0880","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1016\/j.vaccine.2009.03.034","article-title":"Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy","volume":"27","author":"Demento","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115876_bb0885","doi-asserted-by":"crossref","first-page":"E171","DOI":"10.1208\/aapsj0902019","article-title":"Nanosystems for simultaneous imaging and drug delivery to t cells","volume":"9","author":"Fahmy","year":"2007","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115876_bb0890","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1248\/cpb.58.1423","article-title":"Chitosan nanoparticles: a promising system in novel drug delivery","volume":"58","author":"Nagpal","year":"2010","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.addr.2026.115876_bb0895","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1208\/s12249-009-9279-1","article-title":"Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB","volume":"10","author":"Songjiang","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2026.115876_bb0900","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijpharm.2011.07.036","article-title":"Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery","volume":"419","author":"Trapani","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115876_bb0905","doi-asserted-by":"crossref","first-page":"13761","DOI":"10.1523\/JNEUROSCI.4246-09.2009","article-title":"A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection, j. neurosci.: off","volume":"29","author":"Karatas","year":"2009","journal-title":"J. Soc. Neurosci"},{"key":"10.1016\/j.addr.2026.115876_bb0910","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.addr.2011.12.006","article-title":"Polymeric nanoparticles for drug delivery to the central nervous system","volume":"64","author":"Patel","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0915","doi-asserted-by":"crossref","first-page":"13511","DOI":"10.1073\/pnas.0813327106","article-title":"Multiplexed imaging of surface enhanced raman scattering nanotags in living mice using noninvasive raman spectroscopy","volume":"106","author":"Zavaleta","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2026.115876_bb0920","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1021\/jp057170o","article-title":"Calculated absorption and scattering properties of gold nanoparticles of different size, shape, and composition: applications in biological imaging and biomedicine","volume":"110","author":"Jain","year":"2006","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.addr.2026.115876_bb0925","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3762\/bjnano.11.72","article-title":"Key for crossing the BBB with nanoparticles: the rational design","volume":"11","author":"Lombardo","year":"2020","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115876_bb0930","article-title":"The effect of nanoparticle size on the ability to cross the blood-brain barrier: An in vivo study, nanomed","volume":"12","author":"Betzer","year":"2017","journal-title":"Lond. Engl."},{"key":"10.1016\/j.addr.2026.115876_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e05824","article-title":"Electrophysiological effects of polyethylene glycol modified gold nanoparticles on mouse hippocampal neurons","volume":"6","author":"Tuna","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.addr.2026.115876_bb0940","doi-asserted-by":"crossref","first-page":"7578","DOI":"10.3390\/molecules27217578","article-title":"Recent development of nano-carbon material in pharmaceutical application: a review","volume":"27","author":"Jiwanti","year":"2022","journal-title":"Mol. (Basel Switz.)"},{"key":"10.1016\/j.addr.2026.115876_bb0945","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jcp.26899","article-title":"Biomedical applications of carbon nanomaterials: drug and gene delivery potentials","volume":"234","author":"Mohajeri","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.addr.2026.115876_bb0950","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/ac85f3","article-title":"Nanoparticles-based delivery system and its potentials in treating central nervous system disorders","volume":"33","author":"Liu","year":"2022","journal-title":"Nanotechnology"},{"key":"10.1016\/j.addr.2026.115876_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e29726","article-title":"Inorganic nanoparticle-cored dendrimers for biomedical applications: a review","volume":"10","author":"Fateh","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.addr.2026.115876_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117357","article-title":"Inorganic nanoparticles and blood-brain barrier modulation: advancing targeted neurological therapies","volume":"287","author":"Razavi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb0965","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.783831","article-title":"A review on polymer and lipid-based nanocarriers and its application to nano-pharmaceutical and food-based systems","volume":"8","author":"Lu","year":"2021","journal-title":"Front. Nutr."},{"key":"10.1016\/j.addr.2026.115876_bb0970","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12951-025-03109-3","article-title":"Drug delivery strategies with lipid-based nanoparticles for alzheimer's disease treatment","volume":"23","author":"Jang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115876_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114485","article-title":"Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders","volume":"189","author":"Correia","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb0980","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115876_bb0985","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.3892\/ol.2014.2449","article-title":"A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy","volume":"8","author":"Qin","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.addr.2026.115876_bb0990","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/10717544.2017.1344334","article-title":"Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma","volume":"24","author":"Zhang","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2026.115876_bb0995","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1073\/pnas.1516524113","article-title":"In vivo metabolic labeling of sialoglycans in the mouse brain by using a liposome-assisted bioorthogonal reporter strategy","volume":"113","author":"Xie","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2026.115876_bb1000","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/BF02716840","article-title":"Increased circulatory half-life of liposomes after conjunction with dextran","volume":"6","author":"Pain","year":"1984","journal-title":"J. Biosci."},{"key":"10.1016\/j.addr.2026.115876_bb1005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/1061186X.2011.595490","article-title":"Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against parkinson's disease in the MPTP-induced mice model","volume":"20","author":"Xiang","year":"2012","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2026.115876_bb1010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41420-021-00639-1","article-title":"Transferrin-Pep63-liposomes accelerate the clearance of a\u03b2 and rescue impaired synaptic plasticity in early alzheimer's disease models","volume":"7","author":"Yang","year":"2021","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.addr.2026.115876_bb1015","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jconrel.2024.01.019","article-title":"PEGylated-liposomal astaxanthin ameliorates a\u03b2 neurotoxicity and alzheimer-related phenotypes by scavenging formaldehyde","volume":"366","author":"Gu","year":"2024","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.addr.2026.115876_bb1020","article-title":"Physiological barriers and strategies of lipid-based nanoparticles for nucleic acid drug delivery","volume":"36","author":"Hu","year":"2024","journal-title":"Adv. Mater. (Deerf. Beach Fla)"},{"key":"10.1016\/j.addr.2026.115876_bb1025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.15171\/apb.2015.043","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application","volume":"5","author":"Naseri","year":"2015","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.addr.2026.115876_bb1030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.lfs.2018.03.010","article-title":"Therapeutic evaluation of solid lipid nanoparticle of quercetin in pentylenetetrazole induced cognitive impairment of zebrafish","volume":"199","author":"Rishitha","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2026.115876_bb1035","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1089\/rej.2011.1193","article-title":"Delivery of sesamol-loaded solid lipid nanoparticles to the brain for menopause-related emotional and cognitive central nervous system derangements","volume":"14","author":"Kakkar","year":"2011","journal-title":"Rejuvenation Res."},{"key":"10.1016\/j.addr.2026.115876_bb1040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2014.11.014","article-title":"Neuroprotective potential of sesamol and its loaded solid lipid nanoparticles in ICV-STZ-induced cognitive deficits: behavioral and biochemical evidence","volume":"747","author":"Sachdeva","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.addr.2026.115876_bb1045","doi-asserted-by":"crossref","first-page":"150","DOI":"10.34172\/apb.2020.021","article-title":"Nanostructured lipid carriers: a groundbreaking approach for transdermal drug delivery","volume":"10","author":"Chauhan","year":"2020","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.addr.2026.115876_bb1050","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.3390\/molecules25204781","article-title":"Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method","volume":"25","author":"Duong","year":"2020","journal-title":"Mol. (Basel Switz.)"},{"key":"10.1016\/j.addr.2026.115876_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119990","article-title":"Berberine loaded nanostructured lipid carrier for alzheimers disease: design, statistical optimization and enhanced in vivo performance","volume":"285","author":"Raju","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2026.115876_bb1060","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2023.100165","article-title":"Lipid polymer hybrid nanoparticles as potent vehicles for drug delivery in cancer therapeutics","volume":"20","author":"Parveen","year":"2023","journal-title":"Med. Drug Discovery"},{"key":"10.1016\/j.addr.2026.115876_bb1065","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.1038\/s41598-024-58601-x","article-title":"Development of chitosan lipid nanoparticles to alleviate the pharmacological activity of piperine in the management of cognitive deficit in diabetic rats","volume":"14","author":"Darwish","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2026.115876_bb1070","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41578-024-00695-w","article-title":"Precision drug delivery to the central nervous system using engineered nanoparticles","volume":"9","author":"Gao","year":"2024","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.addr.2026.115876_bb1075","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2301067120","article-title":"Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm","volume":"120","author":"Zheng","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2026.115876_bb1080","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.trechm.2024.09.003","article-title":"Strength in numbers: cell penetrating peptide clusters to build next-generation therapeutics","volume":"6","author":"Reeman","year":"2024","journal-title":"Trends Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/pharmaceutics14020279","article-title":"Transferrin receptor-targeted nanocarriers: overcoming barriers to treat glioblastoma","volume":"14","author":"Ramalho","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115876_bb1090","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2013.08.039","article-title":"LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115876_bb1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112999","article-title":"Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases","volume":"221","author":"Teixeira","year":"2023","journal-title":"Colloids Surf. B. Biointerfaces"},{"key":"10.1016\/j.addr.2026.115876_bb1100","series-title":"A new proton sponge polymer synthesized by raft polymerization for intracellular delivery of biotherapeutics","author":"Kurtulu\u015f","year":"2026"},{"key":"10.1016\/j.addr.2026.115876_bb1105","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s11095-022-03296-w","article-title":"Endosomal escape of bioactives deployed via nanocarriers: insights into the design of polymeric micelles","volume":"39","author":"Butt","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115876_bb1110","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s11095-025-03890-8","article-title":"Mechanism of pH-sensitive amphiphilic endosomal escape of ionizable lipid nanoparticles for cytosolic nucleic acid delivery","volume":"42","author":"Lu","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115876_bb1115","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1016\/j.biomaterials.2011.07.069","article-title":"A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein","volume":"32","author":"Huile","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115876_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2024.119473","article-title":"Nervous system exposure of different classes of nanoparticles: a review on potential toxicity and mechanistic studies","volume":"259","author":"Gao","year":"2024","journal-title":"Environ. Res."},{"key":"10.1016\/j.addr.2026.115876_bb1125","series-title":"Insights into nanoparticles-induced neurotoxicity and cope up strategies","author":"Zia","year":"2026"},{"key":"10.1016\/j.addr.2026.115876_bb1130","first-page":"958","article-title":"Bio-inspired drug delivery systems: An emerging platform for targeted cancer therapy, biomater","volume":"6","author":"Ngandeu Neubi","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115876_bb1135","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1039\/C7NR09011K","article-title":"Aggregation of polyethylene glycol polymers suppresses receptor-mediated endocytosis of PEGylated liposomes","volume":"10","author":"Shen","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2026.115876_bb1140","doi-asserted-by":"crossref","first-page":"12108","DOI":"10.1016\/S0021-9258(18)43240-1","article-title":"Mechanism of precipitation of proteins by polyethylene glycols. Analysis in terms of excluded volume","volume":"256","author":"Atha","year":"1981","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1145","article-title":"Cell membrane coating nanotechnology","volume":"30","author":"Fang","year":"2018","journal-title":"Adv. Mater. (Deerf. Beach Fla,)"},{"key":"10.1016\/j.addr.2026.115876_bb1150","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2016.01.024","article-title":"Cell membrane-formed nanovesicles for disease-targeted delivery","volume":"224","author":"Gao","year":"2016","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.addr.2026.115876_bb1155","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12951-023-02004-z","article-title":"Cell membrane-based nanomaterials for theranostics of central nervous system diseases","volume":"21","author":"Li","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115876_bb1160","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12951-025-03572-y","article-title":"Recent advances of engineering cell membranes for nanomedicine delivery across the blood-brain barrier","volume":"23","author":"Yuan","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115876_bb1165","first-page":"625","article-title":"Cell membrane-coated nanoparticles: research advances, nanomed","volume":"15","author":"Zou","year":"2020","journal-title":"Lond. Engl."},{"key":"10.1016\/j.addr.2026.115876_bb1170","doi-asserted-by":"crossref","first-page":"55840","DOI":"10.1021\/acsami.1c16543","article-title":"Neural cell membrane-coated nanoparticles for targeted and enhanced uptake by central nervous system cells","volume":"13","author":"Zhang","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2026.115876_bb1175","article-title":"Nanoparticles coated with brain microvascular endothelial cell membranes can target and cross the blood-brain barrier to deliver drugs to brain tumors, small (weinh. Bergstr. Ger.)","volume":"20","author":"Chen","year":"2024"},{"key":"10.1016\/j.addr.2026.115876_bb1180","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12951-024-02548-8","article-title":"Application and advances of biomimetic membrane materials in central nervous system disorders","volume":"22","author":"Liao","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115876_bb1185","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1016\/j.biomaterials.2009.02.051","article-title":"Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles","volume":"30","author":"Liu","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115876_bb1190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijpharm.2018.03.028","article-title":"RVG29-modified docetaxel-loaded nanoparticles for brain-targeted glioma therapy","volume":"543","author":"Hua","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115876_bb1195","doi-asserted-by":"crossref","first-page":"16288","DOI":"10.1073\/pnas.1210096109","article-title":"Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics","volume":"109","author":"Marrache","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2026.115876_bb1200","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10717544.2020.1745328","article-title":"Neuronal mitochondria-targeted therapy for alzheimer's disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems","volume":"27","author":"Han","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2026.115876_bb1205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jconrel.2023.06.023","article-title":"Cell membrane-based biomimetic vehicles for effective central nervous system target delivery: insights and challenges","volume":"360","author":"Wu","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115876_bb1210","first-page":"735","article-title":"Intranasal drug delivery: opportunities and toxicologic challenges during drug development, drug deliv","volume":"12","author":"Keller","year":"2022","journal-title":"Transl. Res."},{"key":"10.1016\/j.addr.2026.115876_bb1215","first-page":"589","article-title":"Recent advancements in the field of nanotechnology for the delivery of anti-alzheimer drug in the brain region, expert opin","volume":"15","author":"Agrawal","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2026.115876_bb1220","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Erd\u0151","year":"2018","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.addr.2026.115876_bb1225","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2017.09.001","article-title":"Progress in brain targeting drug delivery system by nasal route","volume":"268","author":"Khan","year":"2017","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.addr.2026.115876_bb1230","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/pharmaceutics15030746","article-title":"Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery","volume":"15","author":"Maher","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115876_bb1235","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/1567201819666220401091632","article-title":"Exploring nose to brain nano delivery for effective management of migraine","volume":"20","author":"Tanna","year":"2023","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115876_bb1240","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fbioe.2020.00238","article-title":"Nanoformulations of herbal extracts in treatment of neurodegenerative disorders","volume":"8","author":"Moradi","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2026.115876_bb1245","article-title":"Comparative proteomics inspired self-stimulated release hydrogel reinforces the therapeutic effects of MSC-EVs on alzheimer's disease","volume":"36","author":"Huang","year":"2024","journal-title":"Adv. Mater. (Deerf. Beach Fla)"},{"key":"10.1016\/j.addr.2026.115876_bb1250","article-title":"Customized intranasal hydrogel delivering methylene blue ameliorates cognitive dysfunction against alzheimer's disease","volume":"36","author":"Liu","year":"2024","journal-title":"Adv. Mater. (Deerf. Beach Fla)"},{"key":"10.1016\/j.addr.2026.115876_bb1255","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.1021\/acsnano.1c00453","article-title":"Bioinspired theranostic coordination polymer nanoparticles for intranasal dopamine replacement in parkinson's disease","volume":"15","author":"Garc\u00eda-Pardo","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115876_bb1260","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115354","article-title":"Nanoassemblies designed for efficient nuclear targeting","volume":"211","author":"Skowicki","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb1265","doi-asserted-by":"crossref","DOI":"10.1016\/j.celbio.2025.100016","article-title":"Mitochondria in brain diseases: bridging structural-mechanistic insights into precision-targeted therapies","volume":"1","author":"Liao","year":"2025","journal-title":"Cell Biomater."},{"key":"10.1016\/j.addr.2026.115876_bb1270","doi-asserted-by":"crossref","first-page":"27085","DOI":"10.1039\/D5NR02199E","article-title":"Drug delivery systems for mitochondrial targeting","volume":"17","author":"Tagliavini","year":"2025","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2026.115876_bb1275","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2026.01.008","article-title":"Lysosome-targeting chimeras enable targeted protein degradation","author":"Li","year":"2026","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb1280","doi-asserted-by":"crossref","first-page":"13152","DOI":"10.1021\/acs.jmedchem.1c00910","article-title":"Strategies for structural modification of small molecules to improve blood-brain barrier penetration: a recent perspective","volume":"64","author":"Xiong","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1285","doi-asserted-by":"crossref","first-page":"15642","DOI":"10.1021\/acs.jmedchem.2c00771","article-title":"Identification and characterization of a novel indoleamine 2,3-dioxygenase 1 protein degrader for glioblastoma","volume":"65","author":"Bollu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1290","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \u201cbeyond rule-of-five\u201d chemical space: recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.addr.2026.115876_bb1295","doi-asserted-by":"crossref","first-page":"15960","DOI":"10.1021\/acs.jmedchem.5c00956","article-title":"Discovery of TQ-3959 as a potent and orally bioavailable BTK PROTAC degrader incorporating a novel benzisoxazole-based CRBN ligand for the treatment of b-cell malignancies","volume":"68","author":"Ren","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1300","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1126\/science.178.4064.984","article-title":"Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection","volume":"178","author":"Oldendorf","year":"1972","journal-title":"Sci. (n. Y. N.Y.)"},{"key":"10.1016\/j.addr.2026.115876_bb1305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111571","article-title":"Novel derivatives of anaplastic lymphoma kinase inhibitors: synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib","volume":"182","author":"Radaram","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1310","first-page":"252","article-title":"Drug delivery to the central nervous system: a review, j. pharm. Pharm. Sci.: Publ. Can. Soc. pharm. Sci. Soc. can","volume":"6","author":"Misra","year":"2003","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.addr.2026.115876_bb1315","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s42004-019-0133-4","article-title":"Rivastigmine and metabolite analogues with putative alzheimer's disease-modifying properties in a caenorhabditis elegans model","volume":"2","author":"Dighe","year":"2019","journal-title":"Commun. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1320","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1021\/acs.jmedchem.5c00026","article-title":"Rational design and optimization of a potent IDO1 proteolysis targeting chimera (PROTAC)","volume":"68","author":"Monsen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1325","article-title":"Linker-free PROTACs efficiently induce the degradation of oncoproteins","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115876_bb1330","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3390\/ijms17060806","article-title":"The role of cell-penetrating peptide and transferrin on enhanced delivery of drug to brain","volume":"17","author":"Sharma","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115876_bb1335","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.3390\/pharmaceutics15071999","article-title":"Cell-penetrating and targeted peptides delivery systems as potential pharmaceutical carriers for enhanced delivery across the blood-brain barrier (BBB)","volume":"15","author":"Ghorai","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115876_bb1340","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0092-8674(88)90263-2","article-title":"Cellular uptake of the tat protein from human immunodeficiency virus","volume":"55","author":"Frankel","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115876_bb1345","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0092-8674(88)90262-0","article-title":"Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein","volume":"55","author":"Green","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115876_bb1350","doi-asserted-by":"crossref","first-page":"10444","DOI":"10.1016\/S0021-9258(17)34080-2","article-title":"The third helix of the antennapedia homeodomain translocates through biological membranes","volume":"269","author":"Derossi","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1355","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.88.5.1864","article-title":"Antennapedia homeobox peptide regulates neural morphogenesis","volume":"88","author":"Joliot","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2026.115876_bb1360","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1074\/jbc.M007540200","article-title":"Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery","volume":"276","author":"Futaki","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1365","doi-asserted-by":"crossref","first-page":"30208","DOI":"10.1074\/jbc.M204202200","article-title":"Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate","volume":"277","author":"Mai","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1370","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.molmed.2015.06.005","article-title":"Cell-penetrating peptides: strategies for anticancer treatment","volume":"21","author":"Raucher","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.addr.2026.115876_bb1375","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-penetrating peptides: from basic research to clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2026.115876_bb1380","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.3122323","article-title":"The primary structure and heterogeneity of tau protein from mouse brain","volume":"239","author":"Lee","year":"1988","journal-title":"Sci. (n. Y. N.Y.)"},{"key":"10.1016\/j.addr.2026.115876_bb1385","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1073\/pnas.83.11.4044","article-title":"Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in alzheimer disease","volume":"83","author":"Kosik","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2026.115876_bb1390","first-page":"1227","article-title":"Cell penetrating peptides: the potent multi-cargo intracellular carriers, expert opin","volume":"16","author":"Kardani","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2026.115876_bb1395","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12987-024-00545-5","article-title":"Molecular determinants for brain targeting by peptides: a meta-analysis approach with experimental validation","volume":"21","author":"Cavaco","year":"2024","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.addr.2026.115876_bb1400","article-title":"Systemic administration of neurotransmitter-derived lipidoids-PROTACs-DNA nanocomplex promotes tau clearance and cognitive recovery for alzheimer's disease therapy","volume":"13","author":"Gong","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2026.115876_bb1405","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/s41467-025-60039-2","article-title":"DNA nanoflower oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases","volume":"16","author":"Ge","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115876_bb1410","article-title":"Advancements in aptamer-driven DNA nanostructures for precision drug delivery","volume":"11","author":"Safarkhani","year":"2024","journal-title":"Adv. Sci. Weinh. Baden-Wurtt. Ger."},{"key":"10.1016\/j.addr.2026.115876_bb1415","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tibtech.2022.08.011","article-title":"Novel DNA nanoflower biosensing technologies towards next-generation molecular diagnostics","volume":"41","author":"Sheng","year":"2023","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.addr.2026.115876_bb1420","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-019-0658-x","article-title":"ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles","volume":"7","author":"An","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.addr.2026.115876_bb1425","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00415-009-5404-z","article-title":"Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration","volume":"257","author":"Seelaar","year":"2010","journal-title":"J. Neurol."},{"key":"10.1016\/j.addr.2026.115876_bb1430","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115876_bb1435","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.addr.2026.115876_bb1440","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","article-title":"Challenges to curing primary brain tumours","volume":"16","author":"Aldape","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2026.115876_bb1445","article-title":"Proteolysis-targeting chimera (PROTAC): is the technology looking at the treatment of brain tumors?, front. Cell","volume":"10","author":"Lospinoso Severini","year":"2022","journal-title":"Dev. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb1450","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41418-020-00696-6","article-title":"The role of e3 ubiquitin ligases in the development and progression of glioblastoma","volume":"28","author":"Humphreys","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.addr.2026.115876_bb1455","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1158\/2159-8290.CD-16-0217","article-title":"BRD4 connects enhancer remodeling to senescence immune surveillance","volume":"6","author":"Tasdemir","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2026.115876_bb1460","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41375-018-0044-x","article-title":"Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma","volume":"32","author":"Zhang","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2026.115876_bb1465","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115876_bb1470","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106767","article-title":"BRD4: new hope in the battle against glioblastoma","volume":"191","author":"Duan","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"2013","key":"10.1016\/j.addr.2026.115876_bb1475","first-page":"3670","article-title":"BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses","volume":"190","author":"Belkina","year":"1950","journal-title":"J. Immunol. (Baltim. Md)"},{"key":"10.1016\/j.addr.2026.115876_bb1480","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the e3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb1485","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1016\/j.apsb.2025.03.018","article-title":"PROTAC-loaded nanocapsules degrading BRD4 for radio-chemotherapy sensitization in glioblastoma","volume":"B 15","author":"Guo","year":"2025","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.addr.2026.115876_bb1490","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.apsb.2017.09.008","article-title":"Substance p-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma","volume":"B 8","author":"Ruan","year":"2018","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.addr.2026.115876_bb1495","article-title":"Biomimetic hybrid PROTAC nanovesicles block multiple DNA repair pathways to overcome temozolomide resistance against orthotopic glioblastoma","volume":"37","author":"Xu","year":"2025","journal-title":"Adv. Mater. (Deerf. Beach Fla,)"},{"key":"10.1016\/j.addr.2026.115876_bb1500","doi-asserted-by":"crossref","first-page":"8741","DOI":"10.1021\/acs.nanolett.4c02287","article-title":"Ultrasound-activated PROTAC prodrugs overcome immunosuppression to actuate efficient deep-tissue sono-immunotherapy in orthotopic pancreatic tumor mouse models","volume":"24","author":"Liu","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2026.115876_bb1505","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.matt.2020.10.002","article-title":"Cascade drug-release strategy for enhanced anticancer therapy","volume":"4","author":"Zhang","year":"2021","journal-title":"Matter"},{"key":"10.1016\/j.addr.2026.115876_bb1510","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acsnano.4c11903","article-title":"Strategy and design of in situ activated protein hydrolysis targeted chimeras","volume":"19","author":"Lv","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115876_bb1515","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jconrel.2024.08.032","article-title":"Controlled bioorthogonal activation of bromodomain-containing protein 4 degrader by co-delivery of PROTAC and pd-catalyst for tumor-specific therapy","volume":"374","author":"Li","year":"2024","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.addr.2026.115876_bb1520","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202510641","article-title":"Tandem-activatable PROTAC prodrug for tumor biomarker-driven near-infrared opto-proteolysis","volume":"64","author":"Lu","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.addr.2026.115876_bb1525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113889","article-title":"Discovery of PT-65 as a highly potent and selective proteolysis-targeting chimera degrader of GSK3 for treating alzheimer's disease","volume":"226","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1530","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1021\/acs.jmedchem.3c00274","article-title":"Discovery of small-molecule degraders for alpha-synuclein aggregates","volume":"66","author":"Tong","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1535","article-title":"PROTAC-mediated degradation of mHTT aggregates attenuates neurotoxicity in cellular and r6\/2 mouse models of huntingtons disease","author":"Lu","year":"2026","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115876_bb1540","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1038\/s41388-024-03121-1","article-title":"BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression","volume":"43","author":"Kong","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2026.115876_bb1545","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.4103\/1673-5374.308075","article-title":"Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system","volume":"16","author":"Ma","year":"2021","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.addr.2026.115876_bb1550","doi-asserted-by":"crossref","first-page":"11454","DOI":"10.1021\/acs.jmedchem.2c00844","article-title":"Progress and challenges in targeted protein degradation for neurodegenerative disease therapy","volume":"65","author":"Fang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2026.115876_bb1555","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1128\/JVI.07194-11","article-title":"Limited transferrin receptor clustering allows rapid diffusion of canine parvovirus into clathrin endocytic structures","volume":"86","author":"Cureton","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2026.115876_bb1560","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/pharmaceutics16101328","article-title":"Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine","volume":"16","author":"Serrano","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115876_bb1565","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3390\/pharmaceutics15071916","article-title":"Artificial intelligence in pharmaceutical technology and drug delivery design","volume":"15","author":"Vora","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115876_bb1570","series-title":"Data-driven design of PROTAC linkers to improve PROTAC cell membrane permeability","author":"Murakami","year":"2025"},{"key":"10.1016\/j.addr.2026.115876_bb1575","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1038\/s41467-024-49979-3","article-title":"Application of machine learning models for property prediction to targeted protein degraders","volume":"15","author":"Peteani","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115876_bb1580","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3390\/pharmaceutics14112257","article-title":"Emerging artificial intelligence (AI) technologies used in the development of solid dosage forms","volume":"14","author":"Jiang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115876_bb1585","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1016\/j.xphs.2021.04.013","article-title":"Applications of machine learning in solid oral dosage form development","volume":"110","author":"Lou","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115876_bb1590","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jare.2024.08.002","article-title":"DeepB3P: a transformer-based model for identifying blood-brain barrier penetrating peptides with data augmentation using feedback GAN","volume":"73","author":"Tang","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.addr.2026.115876_bb1595","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115876_bb1600","doi-asserted-by":"crossref","first-page":"36106","DOI":"10.1021\/acsnano.4c15013","article-title":"AI-validated brain targeted mRNA lipid nanoparticles with neuronal tropism","volume":"19","author":"Sela","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115876_bb1605","doi-asserted-by":"crossref","first-page":"616","DOI":"10.6026\/97320630017616","article-title":"Views on artificial intelligence (AI) assisted clinical trials","volume":"17","author":"Balasundaram","year":"2021","journal-title":"Bioinformation"},{"key":"10.1016\/j.addr.2026.115876_bb1610","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s43441-019-00030-4","article-title":"Improving clinical trial participant prescreening with artificial intelligence (AI): a comparison of the results of AI-assisted vs standard methods in 3 oncology trials","volume":"54","author":"Calaprice-Whitty","year":"2020","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.addr.2026.115876_bb1615","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188572","article-title":"The case for AI-driven cancer clinical trials - the efficacy arm in silico","volume":"1876","author":"Kolla","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.addr.2026.115876_bb1620","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12916-019-1426-2","article-title":"Key challenges for delivering clinical impact with artificial intelligence","volume":"17","author":"Kelly","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.addr.2026.115876_bb1625","series-title":"Addressing bias in big data and AI for health care: a call for open science","volume":"2","author":"Norori","year":"2021"},{"key":"10.1016\/j.addr.2026.115876_bb1630","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2026.115876_bb1635","first-page":"219","article-title":"Next steps for targeted protein degradation, cell","volume":"32","author":"Krone","year":"2025","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb1640","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb1645","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115876_bb1650","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","article-title":"Autophagy: renovation of cells and tissues","volume":"147","author":"Mizushima","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.addr.2026.115876_bb1655","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101464","article-title":"Autophagy in alzheimers disease pathogenesis: therapeutic potential and future perspectives","volume":"72","author":"Zhang","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.addr.2026.115876_bb1660","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","article-title":"The roles of PINK1, parkin, and mitochondrial fidelity in parkinson's disease","volume":"85","author":"Pickrell","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.addr.2026.115876_bb1665","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.addr.2026.115876_bb1670","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1021\/acschembio.1c00693","article-title":"Modulation of phosphoprotein activity by phosphorylation targeting chimeras (PhosTACs)","volume":"16","author":"Chen","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb1675","article-title":"Targeted dephosphorylation of tau by phosphorylation targeting chimeras (PhosTACs) as a therapeutic modality","author":"Hu","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115876_bb1680","first-page":"1064","article-title":"Molecular glues for protein-protein interactions: progressing toward a new dream, cell","volume":"31","author":"Konstantinidou","year":"2024","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2026.115876_bb1685","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117297","article-title":"Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potential","volume":"242","author":"Eladl","year":"2025","journal-title":"Biochem. Pharmacol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:18:44Z","timestamp":1783163924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26001109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":337,"alternative-id":["S0169409X26001109"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115876","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering brain-penetrant PROTACs: Bridging molecular design and CNS delivery","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115876"}}